Scope
NICE NG217 covers epilepsy diagnosis, seizure-specific treatment, medicine safety, emergencies and ongoing care across childhood and adulthood. This selected summary prioritises first-seizure assessment, common first-line choices, reproductive precautions, convulsive status epilepticus, specialist escalation and safe withdrawal. Treatment must match seizure type and the individual’s circumstances.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Confirm the diagnosis and identify mimics
- Refer a first suspected seizure or recurrence after remission urgently for specialist assessment within 2 weeks. Children need a paediatrician with first-seizure expertise; adults need a clinician experienced in seizure assessment and epilepsy diagnosis. [1]
- Take a detailed history and examination, using eyewitness accounts or video when available. Obtain a 12-lead ECG after a first suspected seizure to assess cardiac mimics, and consider metabolic causes such as hypoglycaemia. [1]
- Consider awake EEG to support a clinically suspected epilepsy diagnosis, not to exclude epilepsy. If requested after a first seizure, perform it ideally within 72 hours; a normal routine test can be followed by a sleep-deprived EEG after discussion. [1]
- For people diagnosed with epilepsy, offer epilepsy-protocol MRI within 6 weeks of the MRI referral, except in idiopathic generalised epilepsy or self-limited epilepsy with centrotemporal spikes. Consider CT when MRI is contraindicated; do not perform CT after a typical seizure in established epilepsy in the emergency department unless there are other concerns. [1]
Start and adjust treatment according to epilepsy type
- Start an antiseizure medicine once epilepsy is confirmed. After a first unprovoked seizure, consider treatment for neurological deficit, unequivocal epileptic EEG activity, structural brain abnormality or an unacceptable recurrence risk after discussion. [1]
- Use monotherapy whenever possible and review the diagnosis if seizures persist despite an optimal first-line dose. If changing monotherapy, introduce the second medicine slowly while maintaining the first. If the second succeeds, slowly taper the first; if the second fails, slowly taper it and consider an alternative. [1]
- If monotherapy fails, consider add-on treatment with careful titration and frequent review for adverse effects, including sedation. Use the regimen offering the best balance of seizure control and tolerability. [1]
- Refer to tertiary epilepsy services for diagnostic uncertainty, drug resistance, intolerable treatment effects or a need for specialised investigation or treatment. NICE specifies assessment within 4 weeks for these indications. Refer children within 2 weeks if aged under 3, aged under 4 with myoclonic seizures, having a unilateral structural lesion, or showing deterioration in behaviour, speech or learning. [1]
Use seizure-specific first-line choices
- For focal seizures, consider lamotrigine or levetiracetam first; try the other if the initial option fails. For generalised tonic-clonic seizures, NICE offers lamotrigine, levetiracetam or valproate, with valproate subject to the reproductive-safety restrictions. [1]
- Offer ethosuximide first for absence seizures alone. Recognize that carbamazepine, gabapentin, oxcarbazepine, phenobarbital, phenytoin, pregabalin, tiagabine and vigabatrin can exacerbate absence seizures; coexisting seizure types, or risk of them, need a different pathway. [1]
- For myoclonic seizures, offer levetiracetam or valproate subject to valproate safety restrictions. Seek tertiary paediatric neurology advice for children younger than 4; lamotrigine can occasionally worsen myoclonus. [1]
Address reproductive risks before prescribing
- Under the cited UK safety measures, do not start valproate for the first time below age 55 unless two specialists independently document that no effective, tolerated alternative exists or compelling reasons make reproductive risks inapplicable. [1]
- For women and girls who could become pregnant, valproate requires unsuccessful alternatives, full discussion of fetal risks and the Pregnancy Prevention Programme where appropriate. Topiramate likewise must not be used without fulfilling its Pregnancy Prevention Programme conditions. [1]
- Advise boys and men taking valproate to use effective contraception (condoms plus contraception used by a female sexual partner) during treatment and for 3 months after stopping. Men planning a family within the next year need specialist review of medication options. [1]
- Refer women planning pregnancy or already pregnant for specialist medication review and shared obstetric care. Emphasize adherence and do not stop antiseizure medicines without medical supervision; balance fetal drug risks against uncontrolled seizures. [1]
Treat prolonged or recurrent convulsions as emergencies
- Convulsive seizures lasting at least 5 minutes require immediate resuscitation and emergency treatment. Follow an immediately available individual plan; otherwise use buccal midazolam or rectal diazepam in the community, or intravenous lorazepam where IV access and resuscitation facilities are immediately available. [1]
- For convulsive status epilepticus, if the first benzodiazepine dose fails, call emergency services in the community or seek expert guidance in hospital. Follow the immediately available individual plan or give a second dose if seizures continue 5–10 minutes after the first; look for causes such as hypoglycaemia, eclampsia or alcohol withdrawal. [1]
- For convulsive status epilepticus unresponsive to two benzodiazepine doses, give intravenous levetiracetam, phenytoin or valproate with the relevant valproate precautions. If seizures persist, consider an alternative second-line treatment under expert guidance; if the second-line options tried fail, consider phenobarbital or general anaesthesia under expert guidance. [1]
- Repeated or cluster seizures—typically at least three self-terminating events in 24 hours—are a medical emergency. Follow the emergency plan or consider an immediate benzodiazepine, and agree a future plan when recurrence is a concern. [1]
Review ongoing risk, surgical options and withdrawal
- Arrange at least annual adult reviews for drug resistance, learning disability, elevated SUDEP risk, serious comorbidity, long-term medicine risks or interactions, or pregnancy potential while taking high-risk teratogenic antiseizure medicines. Children need individually tailored reviews at least every 12 months. [1]
- Discuss individual epilepsy-related mortality and SUDEP risk from diagnosis. Support adherence, address uncontrolled tonic-clonic seizures and discuss nighttime supervision for those with sleep-related seizures and higher assessed mortality risk. [1]
- Refer drug-resistant epilepsy for consideration of resective-surgery assessment even if MRI shows no abnormality. Learning disability or a genetic diagnosis alone must not exclude an otherwise indicated referral. [1]
- After 2 seizure-free years, assess recurrence risk individually before considering withdrawal. If agreed, taper most medicines typically over at least 3 months, longer for benzodiazepines or barbiturates, and withdraw multiple medicines one at a time. [1]
- Consider drug-level monitoring for uncontrolled seizures, adverse effects, poor adherence or conditions requiring closer supervision such as pregnancy or renal failure. Check interactions: some antiseizure medicines reduce hormonal-contraceptive effectiveness, while oestrogen can reduce lamotrigine effectiveness. [1]
Limitations and use
- This is not the complete childhood epilepsy-syndrome guide, infantile-spasm pathway, add-on drug sequence or genetic-testing algorithm.
- Drug doses, infusion rates, rescue quantities, contraindications and paediatric licensing require the full prescribing and emergency protocols. Some listed uses are off-label.
- The valproate and topiramate restrictions quoted here are UK MHRA measures captured in NICE. Apply current local regulatory requirements and specialist advice; do not abruptly stop an established medicine because of a summary.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Epilepsies in children, young people and adults
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 27 April 2022
- Publisher’s latest update
- 5 August 2026
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.